Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manufacturer For Its Lead Compound, Ph-762, For Both Clinical Trial And Commercial Supply

Phio Pharmaceuticals has entered into a cGMP drug product manufacturing services agreement with a US manufacturer for its lead compound, PH-762, intended for clinical trial and commercial supply. In its Phase 1b trial, 22 patients completed treatment with a 65% pathological response rate in cutaneous squamous cell carcinoma, including an 85% response in the highest-dose cohort. The company plans to engage with the FDA regarding the next stage of clinical development in Q2 2026 and has sufficient cash reserves to sustain operations into the first half of 2027.